New EU Filings Include A Range Of First-Of-Their-Kind Therapies

 
• By Neena Brizmohun

Pridopidine, sebetralstat and mirdametinib, which are novel treatments that are yet to be approved anywhere in the world, are among the latest products for which marketing applications are now under review by the European Medicines Agency.

Pridopidine could become the first treatment for Huntington’s disease with the ability to impact progression • Source: Shutterstock

More from Europe

More from Geography